Gilead Sciences Inc (GILD)

69.94
NASDAQ : Health Care
Prev Close 69.37
Day Low/High 69.05 / 70.07
52 Wk Low/High 65.38 / 103.10
Avg Volume 11.01M
Exchange NASDAQ
Shares Outstanding 1.31B
Market Cap 90.87B
EPS 10.10
P/E Ratio 6.98
Div & Yield 2.08 (3.00%)

Latest News

What You Should Do if This Market Is Overvalued: Cramer's 'Mad Money' Recap (Wednesday 2/22/17)

What You Should Do if This Market Is Overvalued: Cramer's 'Mad Money' Recap (Wednesday 2/22/17)

This market may be cheaper than it looks, especially if companies can keep delivering on the earnings front, says Jim Cramer.

Sarepta Leads Biotech Movers on Voucher Deal News

Sarepta Leads Biotech Movers on Voucher Deal News

Gilead (finally!) has acquired something from Sarepta, even if it is quite small.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Market Not Laced With Kool-Aid; Apple Could Become a Consumer-Products Company: Jim Cramer's View

Market Not Laced With Kool-Aid; Apple Could Become a Consumer-Products Company: Jim Cramer's View

Cramer shares his views on how tired he is of hearing about Kool-Aid, and wonders if Apple could be valued as a consumer-products company one day.

Procter & Gamble, Apple, Home Depot: Doug Kass' Views

Procter & Gamble, Apple, Home Depot: Doug Kass' Views

Doug Kass shares his thoughts on Procter & Gamble, and wonders if the market is about to slip its moorings.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Better Late Than Never, Right?

Some positions call for overdue action, such as getting out of GoDaddy.

Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This

Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This

Some tried-and-true indicators show what's really going on with the market.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Gilead Announces 144-Week Data Evaluating Safety And Efficacy Of Genvoya® For Treatment Of HIV-1 In Treatment-Naïve Adults

Gilead Announces 144-Week Data Evaluating Safety And Efficacy Of Genvoya® For Treatment Of HIV-1 In Treatment-Naïve Adults

Gilead Sciences, Inc. (NASDAQ: GILD) today announced 144-week data from two Phase 3 studies (Studies 104 and 111) evaluating the safety and efficacy of Genvoya ® (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine...

No Bottoming Signs Yet for Gilead

No Bottoming Signs Yet for Gilead

Don't fight the trend of this stock.

Gilead Has 'Good News' But is it Enough?

Gilead Has 'Good News' But is it Enough?

Gilead Sciences' bictegravir suppressed HIV better than rival Glaxo's dolutegravir.

Gilead and 'Good News' Make A Rare, Joint Appearance at HIV Conference

Gilead and 'Good News' Make A Rare, Joint Appearance at HIV Conference

With sales of its hepatitis C drugs falling and an oncology pipeline that has largely disappointed, bictegravir is vitally important for Gilead to defend and grow its dominant HIV franchise.

Gilead Announces Findings From New Preclinical Study Evaluating Novel Class Of HIV Capsid Inhibitors

Gilead Announces Findings From New Preclinical Study Evaluating Novel Class Of HIV Capsid Inhibitors

Gilead Sciences, Inc. (NASDAQ:GILD) today announced findings from a preclinical study evaluating HIV capsid inhibitors (CAIs) for potential use as a long-acting antiretroviral (ARV) treatment.

Gilead Presents New Phase 2 Data On Bictegravir, An Investigational Integrase Strand Transfer Inhibitor For The Treatment Of HIV

Gilead Presents New Phase 2 Data On Bictegravir, An Investigational Integrase Strand Transfer Inhibitor For The Treatment Of HIV

Gilead Sciences, Inc. (NASDAQ: GILD) today announced data from a Phase 2 study evaluating the efficacy, safety and tolerability of a combination of bictegravir (75 mg) (BIC) and emtricitabine/tenofovir alafenamide (200/25...

Allergan Shares Rise on $2.5B Deal for Body-Sculptor Zeltiq

Allergan Shares Rise on $2.5B Deal for Body-Sculptor Zeltiq

Allergan is buying body-sculptor Zeltiq. CEO Brent Saunders deems it to be the Botox of 10 years ago and he expects the deal to be immediately accretive.

These 5 Stocks Are Showing Red Flags in February

These 5 Stocks Are Showing Red Flags in February

These 5 stocks are teetering on the edge of technical breakdowns this month.

5 Toxic Stocks to Avoid

5 Toxic Stocks to Avoid

Watch these five stocks very closely in the weeks ahead. You might be able to find a good place to jump out.

Cramer: Here's the Reason for Allergan's Remarkable Run

Cramer: Here's the Reason for Allergan's Remarkable Run

Static doesn't work in this industry. Pipelines work.

Cramer: Here's the Reason for Allergan's Remarkable Run

Cramer: Here's the Reason for Allergan's Remarkable Run

Static doesn't work in this industry. Pipelines work.

The Nasdaq Is Now At a Record

The Nasdaq Is Now At a Record

The run in tech stocks continues.

Gilead Sciences To Present At The RBC Capital Markets 2017 Global Healthcare Conference On Wednesday, February 22

Gilead Sciences To Present At The RBC Capital Markets 2017 Global Healthcare Conference On Wednesday, February 22

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that John F.

Nasdaq Posts Another Record Close; S&P 500 Rises as Financials Lag

Nasdaq Posts Another Record Close; S&P 500 Rises as Financials Lag

Stocks struggle for direction as oil prices rebound and financials fall, but the Nasdaq and S&P 500 move higher in afternoon trading.

How to Trade Gilead, Parsley Energy, Twitter and More

How to Trade Gilead, Parsley Energy, Twitter and More

Here's how to trade seven of the most active names on the market.

Biotech Tesaro Climbs on Takeout Reports

Biotech Tesaro Climbs on Takeout Reports

The company's shares were up 14% on rumors that it is working with investment banks to consider a sale.

Stocks Turn Mixed as Oil Prices Rebound, Financials Lag, Disney Gains

Stocks Turn Mixed as Oil Prices Rebound, Financials Lag, Disney Gains

Stocks trade mixed as energy shares rebound and financials stocks lag.

Jim Cramer Explains Why Gilead Is a Value Trap

Jim Cramer Explains Why Gilead Is a Value Trap

Jim Cramer explains the problem with Gilead's stock.

Stocks Turn Mixed as Oil Prices Rebound, Disney Jumps

Stocks Turn Mixed as Oil Prices Rebound, Disney Jumps

Stocks trade mixed as oil prices rebound.